Pila Pharma AB (publ) (PILA.ST)
SEK 2.99
(1.87%)
SEK 2.99
(1.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.18 Million SEK | 28.46% |
| 2022 | -7.24 Million SEK | 74.33% |
| 2021 | -28.2 Million SEK | -1904.68% |
| 2020 | -1.4 Million SEK | 65.39% |
| 2019 | -4.06 Million SEK | -18.87% |
| 2018 | -3.42 Million SEK | 48.8% |
| 2017 | -6.68 Million SEK | -953.15% |
| 2016 | -634.32 Thousand SEK | -130.45% |
| 2015 | -275.25 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.54 Million SEK | 50.92% |
| 2024 Q2 | -2.54 Million SEK | 0.0% |
| 2023 Q4 | -5.18 Million SEK | -1567.68% |
| 2023 FY | -5.18 Million SEK | 28.46% |
| 2023 Q1 | -3.38 Million SEK | 53.3% |
| 2023 Q2 | -442 Thousand SEK | 86.93% |
| 2023 Q3 | 353 Thousand SEK | 179.86% |
| 2022 Q2 | -10.81 Million SEK | 39.11% |
| 2022 FY | -7.24 Million SEK | 74.33% |
| 2022 Q1 | -17.76 Million SEK | 37.01% |
| 2022 Q4 | -7.24 Million SEK | -41.4% |
| 2022 Q3 | -5.12 Million SEK | 52.66% |
| 2021 Q1 | -11.23 Million SEK | -698.71% |
| 2021 FY | -28.2 Million SEK | -1904.68% |
| 2021 Q4 | -28.2 Million SEK | 14.04% |
| 2021 Q3 | -32.81 Million SEK | -456.99% |
| 2021 Q2 | -5.89 Million SEK | 47.58% |
| 2020 FY | -1.4 Million SEK | 65.39% |
| 2020 Q4 | -1.4 Million SEK | 0.0% |
| 2019 FY | -4.06 Million SEK | -18.87% |
| 2018 FY | -3.42 Million SEK | 48.8% |
| 2017 FY | -6.68 Million SEK | -953.15% |
| 2016 FY | -634.32 Thousand SEK | -130.45% |
| 2015 FY | -275.25 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | 84.395% |
| Biovica International AB (publ) | -58.73 Million SEK | 91.179% |
| Cantargia AB (publ) | -139.74 Million SEK | 96.293% |
| CombiGene AB (publ) | -101.44 Million SEK | 94.893% |
| Cyxone AB (publ) | -16.67 Million SEK | 68.921% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -74.324% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 82.368% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 90.729% |
| Fluicell AB (publ) | -2.76 Million SEK | -87.511% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 98.426% |
| Mendus AB (publ) | -96.29 Million SEK | 94.62% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 96.25% |
| I-Tech AB | -83.26 Million SEK | 93.778% |
| Intervacc AB (publ) | -88.16 Million SEK | 94.123% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 83.773% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 109.734% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 72.818% |
| OncoZenge AB (publ) | -12.62 Million SEK | 58.97% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 89.624% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 103.12% |
| Lipum AB (publ) | -8.46 Million SEK | 38.796% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 89.643% |
| Ziccum AB (publ) | -2.13 Million SEK | -142.439% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.146% |
| Genovis AB (publ.) | -43.94 Million SEK | 88.209% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.555% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 93.813% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 86.844% |
| Aptahem AB (publ) | 2.9 Million SEK | 278.122% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 98.447% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 95.999% |
| Kancera AB (publ) | -45.69 Million SEK | 88.661% |
| Saniona AB (publ) | 40.44 Million SEK | 112.809% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 88.542% |
| AcouSort AB (publ) | -23.98 Million SEK | 78.4% |
| Xintela AB (publ) | -7.8 Million SEK | 33.655% |
| Abliva AB (publ) | -57.24 Million SEK | 90.949% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 93.697% |
| Amniotics AB (publ) | -5.63 Million SEK | 8.009% |
| 2cureX AB (publ) | -13.4 Million SEK | 61.345% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -139.746% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 195.943% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 103.846% |
| Biosergen AB | -1.88 Million SEK | -175.142% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 125.26% |
| Corline Biomedical AB | -17.01 Million SEK | 69.545% |
| NextCell Pharma AB | -46.79 Million SEK | 88.927% |
| Nanologica AB (publ) | -9.38 Million SEK | 44.813% |
| LIDDS AB (publ) | -13.51 Million SEK | 61.657% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 97.339% |
| BioInvent International AB (publ) | -236.3 Million SEK | 97.808% |
| SynAct Pharma AB | -61.75 Million SEK | 91.611% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 75.807% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 60.837% |
| Alzinova AB (publ) | -21.22 Million SEK | 75.592% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 75.083% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 92.258% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 93.813% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -461.313% |
| Simris Alg AB (publ) | 85.07 Million SEK | 106.09% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 93.688% |